Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.13 USD | +2.47% | +1.96% | -13.99% |
Financials (USD)
Sales 2024 * | 512M | Sales 2025 * | 618M | Capitalization | 3.42B |
---|---|---|---|---|---|
Net income 2024 * | -556M | Net income 2025 * | -484M | EV / Sales 2024 * | 6.21 x |
Net cash position 2024 * | 235M | Net cash position 2025 * | 297M | EV / Sales 2025 * | 5.05 x |
P/E ratio 2024 * |
-6.29
x | P/E ratio 2025 * |
-7.72
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.55% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | +2.47% | ||
1 week | +1.96% | ||
Current month | +2.47% | ||
1 month | -4.79% | ||
3 months | -23.39% | ||
6 months | +2.42% | ||
Current year | -13.99% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | 0.00% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 41.13 | +2.47% | 889,598 |
24-05-31 | 40.14 | +3.86% | 1,518,406 |
24-05-30 | 38.65 | +1.34% | 666,156 |
24-05-29 | 38.14 | -3.05% | 532,826 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.99% | 3.33B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- RARE Stock